Response of LNCaP spheroids after treatment with an α-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591)

Cancer Research

Volumn 61, Issue 5, 2001, Pages 2008-2014

  Ballangrud, Åse M ^a   Yang, Wei Hong ^a   Charlton, David E ^c   McDevitt, Michael R ^a   Hamacher, Klaus A ^a   Panageas, Katherine S ^a   Ma, Dangshe ^a   Bander, Neil H ^b   Scheinberg, David A ^a   Sgouros, George ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Gina Cody School of Engineering and Computer Science   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ALPHA RADIATION; ANTIBODY RESPONSE; ARTICLE; CANCER RADIOTHERAPY; CELL KILLING; DRUG HALF LIFE; DRUG TARGETING; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIOIMMUNOTHERAPY; SPHEROID CELL; TARGET CELL; TUMOR VOLUME; VASCULARIZATION;

ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; BISMUTH; CARBOXYPEPTIDASES; CELL DIVISION; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOTOXINS; MALE; MICROSCOPY, CONFOCAL; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 0035266150     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. 131I]anti-B1 (anti-CD20) antibody
2. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
3. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
4. Microvascular permeability of normal and neoplastic tissues
5. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules
6. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure
7. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues
8. A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier
9. Plasmapheresis in radioimmunotherapy of micrometastases: A mathematical modeling and dosimetrical analysis
10. Radioimmunotherapy with α-particle-emitting immunoconjugates
11. A model of cell inactivation by α-particle internal emitters
12. Cell and environment interactions in tumor microregions: The multicell spheroid model
13. A tumor spheroid model for antibody-targeted therapy of micrometastases
14. Optimization of radioimmunotherapy using human malignant melanoma multicell spheroids as a model
15. Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: Uptake, retention kinetics, and dosimetric evaluation
16. Growth of prostatic cancer cells, DU 145, as multicellular spheroids and effects of estramustine
17. Growth and characterization of LNCaP prostate cancer cell spheroids
18. 131I-anticarcinoembryonic antigen therapy of LS174T human colon adenocarcinoma spheroids
19. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells
20. High-linear energy transfer (LET) α versus low-LET β emitters in radioimmunotherapy of solid tumors: Therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model
21. Studies on the red marrow dosimetry in radioimmunotherapy: An experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with β-, Auger/conversion electron-, or α-emitters
22. Vascular targeted radioimmunotherapy with 213Bi-an α-particle emitter
23. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate
24. Targeted α-particle therapy for myeloid leukemias: A phase 1 trial of bismuth-213-HUM195 (anti-CD33)
25. Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia
26. Astatine-211-labeled radiotherapeutics: An emerging approach to targeted α-particle radiotherapy
27. Phase I trial of α-particle-emitting astatine-211 labeled chimeric antitenascin antibody in recurrent malignant glioma patients
28. Bone metastases: Biology and therapy
29. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells
30. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice
31. LNCaP model of human prostatic carcinoma
32. Expression of the prostate-specific membrane antigen
33. A simplified method for production and growth of multicellular tumor spheroids
34. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
35. Constitutive and antibody-induced internalization of prostate-specific membrane antigen
36. An α-particle emitting bismuth-213 labeled antibody (J591) to the external domain of prostate specific membrane antigen
37. The kinetics of antibody binding to membrane antigens in solution and at the cell surface
38. Prostate-specific membrane antigen expression in normal and malignant human tissues
39. Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia
40. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M 195
41. An effective chelating agent for labeling of monoclonal antibody with 212Bi for α-particle mediated radioimmunotherapy
42. Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labeling of monoclonal antibodies with bismuth-212 α-particle emitter
43. α-Emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity, and chemistry
44. Preparation of α-emitting 213Bi-labeled antibody constructs for clinical use
45. An 225Ac/213Bi generator system for therapeutic clinical applications: Construction and operation
46. Parametric images of antibody pharmacokinetics in Bi-213-HuM195 therapy of leukemia
47. Radiation effects in spheroids of cells exposed to α emitters
48. Stopping and range of ions in matter (SRIM96)
49. Longitudinal data analysis for discrete and continuous outcomes
50. Modeling and dosimetry of monoclonal antibody MI95 (anti-CD33) in acute myelogenous leukemia
51. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations
52. Radioimmunotherapy with α-particle-emitting radioimmunoconjugates
53. Radioimmunotherapy with α-emitting nuclides
54. Report of the task group on reference man
55. β versus α-emitter dose-response analysis in patients
56. Drug and radiation resistance in spheroids: Cell contact and kinetics
57. Relationships between tumor size and curability for uniformly targeted therapy with β-emitting radionuclides